Oracle announced today that it will acquire Relsys International Inc., a maker of drug safety and risk management applications tailored to give pharmaceutical, life sciences, and even medical device companies greater control over and visibility into the end-to-end processes of drug safety management.
Privately held Relsys will be folded into Oracle’s Health Sciences Global Business Unit at the deal’s close, which Oracle expects sometime in the first half of 2009. Terms of the deal were not disclosed.
The Relsys flagship product, Argus Safety, is an adverse-effect data management and regulatory reporting tool. Built on a single global database to track case reports regardless of where in the world they originated, the Argus suite includes risk management, analytics, pharmacovigilance quality assurance, and reporting tools, among other capabilities. The Web-based Argus software is built on an open, modular architecture that easily integrates with Oracle applications, the companies said today.
While Oracle has yet to define a product roadmap or integration timeline, officials said they believe the combination of Relsys’ offerings and Oracle’s technology, including its database, collaboration tools, ERP, and CRM, will provide a comprehensive safety and risk management solution that spans clinical work, post-market surveillance, and patient care.